NFLX (Netflix) — Single-Name Thesis #

⚠️ CHARTER EXCEPTION (authorized 2026-06-21). This is a deliberate, user-authorized override of resources/strategy-charter.md §6 (new money → tilt only) and §7 (no single-name picks). It is not a charter-compliant position. It is logged in charter §8 so a future session does not mistake it for a violation. The conviction it expresses (quality compounder at a fair price) is otherwise harvested through IS3Q, where NFLX already sits at ~1.1%. The user accepted the trade-off: this reopens idiosyncratic single-name risk the pivot was built to close. Hold the line — one exception, not two.

Date: 2026-06-21 · Price at thesis: $77.38 (post 10:1 split, Nov 2025) · Data: same-day agent pulls (yfinance + Finnhub + web), 2026-06-21.

1. Hypothesis #

Netflix is a high-quality, wide-moat compounder whose stock fell ~42% from its post-split high ($134 → $77, ~3% off the 52-wk low) on multiple compression and sentiment, not a fundamental break. Through the entire decline revenue grew ~16% and operating margin expanded to ~29.5%. At ~25x clean forward earnings the multiple prices in ~8.5% growth (Graham implied) against a business plausibly compounding earnings low-teens via ad scaling + margin expansion + buybacks. Buy the quality at a fair price; let it compound. Not a deep-value bet — a GARP one.

It leans on the corpus's one HIGH-reliability investable edge — quality (QMJ, Asness-Frazzini-Pedersen 2019; gross profitability, Novy-Marx 2013; Buffett's-alpha quality-low-beta, Frazzini-Kabiller-Pedersen 2018). NFLX scores on all three MSCI Quality pillars: ROE ~48%, net debt/EBITDA ~0.3x, stable growing earnings.

2. Valuation — done honestly (clean of one-time items) #

Q1 2026 net income / FCF were inflated by a one-time ~$2.8B WBD termination fee (Paramount funded the breakup fee after Netflix lost the WBD bid). Strip it:

Graham growth-addendum test (shr-004): implied growth = (25 − 8.5)/2 ≈ 8.5%. Achievable ≈ 12–14% (revenue +13–16%, margin expansion, ~6.7% share-count shrink). Implied < achievable → passes with margin, though thinner than the headline 25x P/E suggests. Skip PEG (shr-005): FY26 "+42% EPS" is fee-inflated noise.

3. Bull case #

• Ads doubling — ~$1.5B (2025) → ~$3B (2026), ~250M ad-tier MAUs, ~7% of a huge ad market. The credible next growth leg, not narrative.
• Margin expansion is banked — 17.8% (2022) → 29.5% (2025) operating margin.
• Shareholder-friendly capital — ~$9B buyback (2025), float shrinking ~6.7% since 2022, accretive at $77. Fortress balance sheet, net debt/EBITDA ~0.3x.
• Pricing power — recurring price hikes holding without material churn.

4. Bear case (the real risks) #

• Growth plateau — guide decelerates to ~13% (26) → ~12% (27); Street FY27 EPS consensus only +6.6%. The easy margin-inflection gains may be largely done.
• Growth quality — leans on price hikes more than organic sub adds; ad ramp could slow.
• Competition consolidating — lost WBD (to Paramount) and Roku (to Fox); a combined Paramount-WBD (HBO Max + Discovery + Paramount) is a stronger rival.
• Uniform insider selling (shr-002) — both co-CEOs + CFO + CLO + Hastings all sold at $85–96, zero buys (likely 10b5-1, but no one's buying the dip).
• Not actually cheap — ~33x clean FCF is a fair price, not a margin-of-safety bargain.

5. Red-flag check (shr-020, same-day 2026-06-21) #

🟡 Price (downtrend, near low) · 🟡 News (soft Q2 guide, leadership change, M&A losses) · 🟡 Insiders (uniform C-suite selling) · 🟢 Analysts (Buy-tilt, PT $114) · ⚪ Dividend (none) · 🟢 Balance sheet (no dilution, fortress) · 🟡 FCF quality (one-time fee) · 🟡 Growth durability. No thesis-breaking RED. Multiple AMBERs → smaller starter (shr-034).

6. Entry & tranche plan (smaller starter per shr-034 + shr-013) #

Downtrend + multiple ambers + no near-term positive catalyst → start small, keep dry powder.

• T1 (now): ~40–50% of intended — a starter to participate if it reverses.
• T2: add on (a) further weakness without a thesis break (average down at a wider MoS), or (b) the Q2 2026 print (~July) — the catalyst that resolves the deceleration question (Q2 guide was last quarter's soft spot, so the bar is low).
• Sizing frame: single-name idiosyncratic bet → cap well below the IS3Q tilt. Recommended full position ≈ €300–400 (~one legacy-name unit), T1 ≈ €150–200. Fund from GANX exit proceeds / contributions. DEGIRO is manual + whole-share — verify share count & FX in-app (≈ 2 sh T1, ≈ 5 sh full at $77.38, EUR/USD ~1.17). Confirm the euro amount before executing.

7. Kill conditions — fundamental stops only (shr-016, shr-024; NO price stop) #

A price drop with intact fundamentals increases margin of safety (charter §7 bans price stops). Exit/re-score on:

• Ad revenue misses the ~$3B / ~2x 2026 scaling materially — the next-leg growth driver fails.
• Operating margin sustained < ~25% (non-seasonal, 2+ quarters) — margin-expansion thesis breaks.
• Revenue growth < high-single-digits, 2 consecutive quarters FX-neutral — saturation + pricing power exhausted.
• Pricing-power break — a price hike triggers material churn (ARM/engagement roll over).
• Capital allocation turns hostile — buyback halted + a large debt-funded dilutive acquisition.

8. Re-evaluation / profit frame (shr-016 adapted for a compounder) #

No mechanical take-profit ladder — hold while quality + growth intact. Re-assess valuation discipline if it re-rates back toward ~30x+ clean forward earnings (~$115+, ≈ analyst mean PT), where the growth-addendum margin compresses. Trim into strength only if growth has also decelerated.

9. Provenance & caveats (shr-026 / shr-041 — verify your own outputs) #

• All figures from same-day (2026-06-21) agent pulls; the Q1 8-K could not be fetched directly (SEC 403) — operating-margin/guidance EPS are from secondary sources, confirm vs the 8-K before the actual fill. One-time WBD fee adjustment applied throughout.
• Watch for split-confusion in any future data (10:1 on 2026-11-17; pre-split prices ~10x).
• This thesis is provisional under the new model — it is an exception, not a template. Do not let it normalize single-name picking (charter §3 diagnosis).